ライフサイエンスコーパス: cell-based therapy

1 e attractive targets for stem and progenitor cell-based therapy.

2 cells for disease modeling and, ultimately, cell-based therapy.

3 d have broad applicability for hematopoietic cell-based therapy.

4 ation, and their suitability for programs of cell-based therapy.

5 so large-scale applications and personalized cell-based therapy.

6 restoration in partial LSCD is possible with cell-based therapy.

7 ides a strategy to sensitize RMS cells for T-cell-based therapy.

8 disorders may now be compelling targets for cell-based therapy.

9 from IRI and suggests their potential use in cell-based therapy.

10 potentially provide an autologous source for cell-based therapy.

11 ngraftment, which is a limiting step of stem cell-based therapy.

12 e immune surveillance, which is critical for cell-based therapy.

13 covery and more widespread use of autologous cell-based therapy.

14 cells (MSCs) are a promising candidate for a cell-based therapy.

15 tforms for disease study, drug screening and cell-based therapy.

16 the use of hiPSC-CM for disease modeling and cell-based therapy.

17 oth mechanistic studies and screening of new cell based therapies.

18 edical research models and for gene and stem cell based therapies.

19 disease modeling, regenerative medicine and cell-based therapies.

20 itinol thin films can improve the effects of cell-based therapies.

21 ts a promising approach to improve safety of cell-based therapies.

22 he forefront of the development of gene- and cell-based therapies.

23 intact cell sheets has shown promise in many cell-based therapies.

24 aluable tool for researchers developing stem cell-based therapies.

25 etabolic disorders foster advanced gene- and cell-based therapies.

26 icines, attention is increasingly turning to cell-based therapies.

27 cumvent the hurdles of traditional gene- and cell-based therapies.

28 of iPS-H, and may be applicable to many stem cell-based therapies.

29 lication in a host of tissue engineering and cell-based therapies.

30 valuable tool with which to evaluate various cell-based therapies.

31 high-quality cells remains an impediment to cell-based therapies.

32 ing, risk prediction, and cell selection for cell-based therapies.

33 ate and function, and for the development of cell-based therapies.

34 H) 1 and IDH2, antibody-based therapies, and cell-based therapies.

35 ll-based monitoring of cancer cells and stem cell-based therapies.

36 sed in DM, potentially exacerbating impaired cell-based therapies.

37 ally improve efficacy of stem and progenitor cell-based therapies.

38 industry is critical for generating new stem cell-based therapies.

39 h as drug screening and potentially also for cell-based therapies.

40 tion would greatly facilitate development of cell-based therapies.

41 ro culture is a common prerequisite for stem cell-based therapies.

42 d could instruct improved protocols for stem cell-based therapies.

43 t importance for application to regenerative cell-based therapies.

44 Cs is particularly attractive for allogeneic cell-based therapies.

45 edge gaps and safety concerns regarding stem cell-based therapies.

46 d models of mtDNA disease and support future cell-based therapies.

47 n essential prerequisite for developing stem cell-based therapies.

48 ation--offer renewed hope for development of cell-based therapies.

49 cines and for the development of effective T cell-based therapies.

50 el treatment strategies for future gene- and cell-based therapies.

51 y allow for future widespread application of cell-based therapies.

52 eful preclinical model for testing gene- and cell-based therapies.

53 omplex will allow better design of gene- and cell-based therapies.

54 diverse lineages for future patient-specific cell-based therapies.

55 in preclinical and clinical applications of cell-based therapies.

56 ic diseases makes them attractive for use in cell-based therapies.

57 maging can be used to non-invasively monitor cell-based therapies.

58 udies of skeletal biology and development of cell-based therapies.

59 is tumor is a candidate for virus-specific T cell-based therapies.

60 improving our ability to achieve successful cell-based therapies.

61 ntigens that can be targeted by subsequent T cell-based therapies.

62 provide new insights for improving allogenic cell-based therapies.

63 tion of the niche with implications for stem cell-based therapies.

64 ay be leveraged to enhance phenotypes for NK cell-based therapies.

65 may impact future design of autologous stem cell-based therapies.

66 tcomes in the treatment of lung disease with cell-based therapies.

67 e potential role of cortical interneurons in cell-based therapies.

68 Cs following TBI might offer new avenues for cell-based therapy, additional intervention is required

69 Clinical trials of bone marrow cell-based therapies after acute myocardial infarction (

70 ecule antagonism of GSK3beta, which enhanced cell-based therapy after vascular injury.

71 implications for improving the efficacy of T cell-based therapies against chronic infectious diseases

72 therapy may thus be needed with emerging NK cell-based therapies against hematopoietic malignancies.

73 ogramming, have shown enormous potential for cell-based therapies against intractable diseases such a

74 ty of adult spinal cord and the potential of cell-based therapies against neuropathic pain.

75 zation process can be used to develop robust cell-based therapy against novel disease targets.

76 attempts and describe the updated status of cell-based therapies aimed at counteracting the skeletal

77 ng functions have important implications for cell-based therapies aimed at modulating inflammation an

78 findings are relevant to the optimization of cell-based therapies aimed at promoting CNS regeneration

79 Cell-based therapies aimed at replenishing renal parench

80 These data suggest that stem cell-based therapies aimed to engineer tissue in vivo ma

81 ate the outcome of stem cell- and progenitor cell-based therapies aimed to restore defunct muscle.

82 associated with retinal diseases makes stem-cell-based therapies an attractive strategy for personal

83 for genetic engineering, development of stem cell-based therapies and basic research on pluripotency

84 ential to enable a new wave of sophisticated cell-based therapies and diagnostics.

85 luripotent stem cells hold great promise for cell-based therapies and drug discovery.

86 anufacturing have the potential to broaden T cell-based therapies and foster new applications beyond

87 d cell manufacturing are poised to broaden T-cell-based therapies and foster new applications in infe

88 observations have direct implications for NK cell-based therapies and highlight the requirement to co

89 supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors an

90 ENS; information required for development of cell-based therapies and models of enteric neuropathies.

91 Cell-based therapies and pre-vascularized tissues have s

92 eating cutaneous wounds, with an emphasis on cell-based therapies and skin transplantation.

93 n is essential for the improvement of immune cell-based therapies and the development of rational com

94 ure are unknown and hamper their use both in cell-based therapy and basic research.

95 ted by progress in the understanding of stem cell-based therapy and growth factor enhancement of the

96 ith autologous tumor lysate-pulsed dendritic cell-based therapy and simultaneously reducing the tumor

97 ponent of genome-editing approaches, ex vivo cell-based therapies, and a diversity of fundamental res

98 ating ARDS, including combination therapies, cell-based therapies, and generic pharmacological compou

99 ation is a cornerstone in manufacturing of T cell-based therapies, and precise control over T cell ac

100 apacities to replace the damaged skeleton in cell-based therapy, and permit further elucidation of th

101 testing of novel therapeutics as well as for cell based therapy approaches.

102 topes make it a viable target for pursuing T cell-based therapy approaches.

103 Cell based therapies are required now to meet the critic

104 Cell-based therapies are a novel potential treatment for

105 Cell-based therapies are a promising intervention for th

106 Cell-based therapies are a promising option in patients

107 RATIONALE: Cell-based therapies are a promising option in patients

108 Regenerative cell-based therapies are associated with limited myocard

109 KEY POINTS: While autologous stem cell-based therapies are currently being tested on elder

110 Cell-based therapies are emerging as a promising approac

111 Cell-based therapies are gaining increasing importance a

112 Cell-based therapies are gaining prominence in treating

113 Cell-based therapies are increasingly focused on allogen

114 The present meta-analysis indicates that cell-based therapies are not only safe but also lead to

115 Although gene- and cell-based therapies are on the horizon for RP and Usher

116 Cell-based therapies are promising alternative therapeut

117 Gene- and cell-based therapies are promising strategies for the tr

118 NK cell-based therapies are promising treatments for blood

119 Cell-based therapies are promising treatments for variou

120 Several cell-based therapies are under pre-clinical and clinical

121 onstrating that the positive effects of such cell-based therapy are mediated by exosomes released fro

122 rative medicine (TE/RM) therapeutics include cell based therapies as well as engineered tissues and n

123 ad applications for enhancing engraftment in cell-based therapies as well as restoring age- and stres

124 tem cells (PSCs) are a leading candidate for cell-based therapies because of their capacity for unlim

125 tremendous promise in tissue engineering and cell-based therapies because of their unique combination

126 igen (HLA) molecules have been targeted by T cell-based therapies, but there has been little progress

127 tent stem cells (PSCs) hold great promise in cell-based therapy, but the genomic instability seen in

128 able approach to enhance the effects of stem cell-based therapies by improving cell retention and eng

129 ncer cells to induce tolerance to allogeneic cell-based therapies by modifying cells to express immun

130 have become an important tool for improving cell-based therapies by promoting cell survival and prot

131 g has the potential to enable more-effective cell-based therapies by using readily available cell sou

132 Recent studies have shown that stem cell-based therapies can improve liver function in a mou

133 Stem-cell-based therapies can potentially reverse organ dysfu

134 seek to test the efficacy of a novel, safer cell-based therapy (CBT) employing ex vivo primed bone m

135 Cell-based therapies (CBTs) are considered the effective

136 Vasculogenic cell-based therapy combined with tissue engineering is a

137 The pursuit of gene and cell-based therapy continues, and device use to help acu

138 eprogramming ECs, are an ideal cell type for cell-based therapy designed to stimulate coronary collat

139 esource for personalized vaccine or adoptive cell-based therapy development.

140 responses that may inform the development of cell-based therapies directed at this virus.

141 chwann cells promise to be a useful tool for cell-based therapies, disease modelling and drug discove

142 tremendous promise in tissue engineering and cell-based therapies due to their unique combination of

143 ration make these cells ideal candidates for cell-based therapies, especially for diseases associated

144 hotopheresis (ECP) is a widely used clinical cell-based therapy exhibiting efficacy in heterogenous i

145 Cell-based therapy exploits modified human cells to trea

146 plant is being applied to the development of cell-based therapies for a variety of CNS disorders.

147 commitment suggests their potential in stem cell-based therapies for acute and chronic lung diseases

148 red to exploit the full potential of myeloid cell-based therapies for AD.

149 Several cell-based therapies for adjunctive treatment of acute m

150 plications for the design of vaccine, Ab and cell-based therapies for autoimmunity, infectious diseas

151 l genome engineering holds great promise for cell-based therapies for cancer, HIV, primary immune def

152 vital for guiding the future development of cell-based therapies for cardiac regeneration.

153 Successful implementation of gene- and cell-based therapies for CF airway disease requires know

154 w harvest, and discussing risks vs benefits, cell-based therapies for chronic stroke, and consent for

155 een primarily studied for the development of cell-based therapies for Duchenne muscular dystrophy, li

156 or the development of protein replacement or cell-based therapies for dystrophic epidermolysis bullos

157 lls (CSCs) is a critical step for developing cell-based therapies for heart failure patients.

158 Continued advances toward cell-based therapies for human disease generate a growin

159 tion potential and may be a useful model for cell-based therapies for infectious and non-infectious l

160 A major obstacle to using bone marrow cell-based therapies for ischemic cardiovascular disease

161 armaceutical applications and development of cell-based therapies for liver diseases.

162 on and limits the effectiveness of gene- and cell-based therapies for muscle disorders.

163 Cell-based therapies for myelin disorders, such as multi

164 technology have engendered keen interest in cell-based therapies for neurological disorders.

165 ES cell-based therapies for neurological repair in TLE requ

166 of Th17 immunity, and open new avenues for T cell-based therapies for Nod2-associated disorders such

167 t work that addresses key challenges of stem cell-based therapies for osteoarthritis and provide exam

168 Stem cell-based therapies for Parkinson's disease are moving

169 on of stem cells and the development of stem cell-based therapies for Parkinson's disease.

170 l in 1997 by Asahara and Isner, the field of cell-based therapies for peripheral arterial disease has

171 modelling inner ear disorders or developing cell-based therapies for profound hearing loss and balan

172 microenvironment may impact the potential of cell-based therapies for recovery and repair following C

173 itutes, vitreous drug release hydrogels, and cell-based therapies for regeneration.

174 be one of the most promising candidates for cell-based therapies for SCI.

175 epair and may serve as inspiration for novel cell-based therapies for skeletal pathologies, such as o

176 ew, we describe recent approaches to develop cell-based therapies for the treatment of AMD.

177 Optimal cell-based therapies for the treatment of muscle degener

178 A major obstacle in the application of cell-based therapies for the treatment of neuromuscular

179 ion of cell behavior and offering customized cell-based therapies for tissue engineering.

180 development and may help guide the design of cell-based therapies for treating retinal dystrophies.

181 ide insights into the design of effective NK cell-based therapies for viral infections.

182 al stromal cells are being investigated as a cell-based therapy for a number of disease processes, wi

183 ve received less attention as an alternative cell-based therapy for animals or even humans.

184 Our design of T-cell-based therapy for cancer has reflected efforts to i

185 e infarcted myocardium remain problematic in cell-based therapy for cardiovascular disease.

186 velopmental pathway and open a potential for cell-based therapy for corneal blindness.

187 herefore, potentially expanding the scope of cell-based therapy for corneal blindness.

188 e further research into the development of a cell-based therapy for deafness.

189 esent a potential for development of a novel cell-based therapy for glaucoma.

190 a potential for development of a novel stem cell-based therapy for glaucoma.

191 lay crucial roles in phenotypic responses to cell-based therapy for heart failure.

192 ed derivatives can potentially be applied to cell-based therapy for human diseases.

193 They might be developed as a cell-based therapy for intestinal inflammatory disorders

194 bitory controls has potential as a powerful, cell-based therapy for neuropathic itch that not only am

195 rogenesis that may ultimately lead to a stem cell-based therapy for osteoarthritis.

196 so is a potential candidate for developing a cell-based therapy for pre-existing autoimmune diseases.

197 olled trial) represents the largest study of cell-based therapy for STEMI completed in the United Sta

198 using this method which may further lead to cell-based therapy for treating corneal endothelial dysf

199 Growing interest in natural killer (NK) cell-based therapy for treating human cancer has made it

200 tem cell-derived interneurons is a promising cell-based therapy for treatment of these disorders.

201 All types of cell-based therapies, from donor lymphocyte infusion to

202 application of protein and peptide therapy, cell-based therapy, genetic therapy, application of scaf

203 success of chimeric antigen receptor (CAR) T-cell based therapies greatly rely on the capacity to ide

204 ches is ushering in a new generation of stem cell-based therapies, greatly expanding their therapeuti

205 d feasibility of the clinical application of cell-based therapy has been demonstrated, and promising

206 Cell-based therapy has been viewed as a promising altern

207 On the basis of several preclinical studies, cell-based therapy has emerged as a potential new therap

208 Stem cell-based therapy has emerged as a potential therapy in

209 Stem cell-based therapy has recently been explored for the tr

210 y and prevent organ rejection; however, Treg cell-based therapies have been hampered by the technical

211 lling after stroke or injury does occur, and cell-based therapies have been used to promote these end

212 Cell-based therapies have shown encouraging results in b

213 Stem cell-based therapies have the potential to fundamentally

214 Stem cell-based therapies hold considerable promise for many

215 Emerging cell-based therapies hold the promise of accomplishing t

216 ion represents the first and most prescribed cell-based therapy; however, clinical safety and efficac

217 These data suggest that to optimize TR1 cell-based therapy, IL-10 receptor expression has to be

218 dition to improvements in indices of angina, cell-based therapies improve cardiovascular outcomes (mo

219 Although clinical studies have shown that cell-based therapies improve wound healing, the recruitm

220 Cs may represent a promising alternative for cell-based therapies in AD.

221 Cell-based therapies in muscular dystrophies have been p

222 treat age-onset diseases and facilitate stem-cell-based therapies in older individuals.

223 ovide significant advantages for autologous, cell-based therapies in regenerative medicine.

224 (i.e., personalized medicine), and enabling cell-based therapies in the clinic.

225 Determining the persistence of cell-based therapies in vivo is crucial to understanding

226 hMSCs) are a promising source for engineered cell-based therapies in which genetic engineering could

227 at least in part, the beneficial effects of cell-based therapy in a post-MI large mammalian model, a

228 ospects in designing and implementing T(reg) cell-based therapy in autoimmunity and transplantation.

229 controlled trials to evaluate the effect of cell-based therapy in patients with refractory angina wh

230 ability, and efficacy of mesenchymal stromal cell-based therapy in pilot clinical trials, including t

231 support future investigation of regulatory B cell-based therapy in the treatment of this disease.

232 Cell-based therapies, including immunoablation followed

233 on, important in free-radical formation; and cell-based therapies, including mesenchymal stem cells i

234 er of 2012, publicly traded companies in the cell-based therapy industry continued to show promising

235 tigation of these cells may help ensure that cell based-therapy is used safely and effectively in hum

236 Replacing lost retinal cells via stem cell-based therapies is an exciting, rapidly advancing a

237 potent stem cells for laboratory studies and cell-based therapies is hampered by their tumor-forming

238 Emerging research on cell-based therapies is opening a new door for patients

239 Cell-based therapy is envisaged as a useful therapeutic

240 A key aspect of cardiac cell-based therapy is the proper integration of newly fo

241 treatments, including cytokine treatment or cell-based therapy, is now available, although not all h

242 a major obstacle to the success of all stem cell-based therapies, many recent studies have sought to

243 terature suggests that current approaches of cell-based therapies may be helpful in ameliorating some

244 tering A2AR antagonists concurrently with NK cell-based therapies may heighten therapeutic benefits b

245 nt preclinical literature suggests that stem-cell-based therapies may offer promise, however the impa

246 y T (iTreg) cells are a promising source for cell-based therapies of established inflammatory and aut

247 rials using mesenchymal stem cells (MSCs) in cell-based therapies of numerous diseases.

248 nction and may provide a source of cells for cell-based therapies of the inner ear.

249 ferentiated cells may be highly suitable for cell-based therapy of chronic hepatocyte-depleting disor

250 tential in vitro, a major limitation for the cell-based therapy of liver disorders and for ex vivo bi

251 for progressive heart failure and death, and cell-based therapies offer new hope for these patients.

252 Cell-based therapies offer the potential to repair and r

253 Of the various cell-based therapy options, mesenchymal stem/stromal cel

254 edicine strengthens prospects for developing cell-based therapies or for promotion of endogenous repa

255 elial stem cells for the development of stem cell-based therapy or bioengineering SG tissues to repai

256 tive S1P3 antagonists for tolerizing DCs for cell-based therapy or for systemic administration for th

257 These developments, along with novel T cell-based therapies, position us to expand the assortme

258 Moreover, clinical trials of cell-based therapies present several unique methodologic

259 This cell-based therapy provides a novel therapeutic strategy

260 Cell-based therapies represent a promising strategy to t

261 Cell-based therapies represent promising strategies for

262 Alternatives using macromolecular, viral, or cell-based therapies show early promise.

263 have important therapeutic implications for cell-based therapy strategies that use mixtures of CSCs

264 at include engineering biological valves and cell-based therapy strategies to replace coronary vascul

265 hence, they might be considered for further cell-based therapy study on wound healing.

266 tumor cells or immune-regulatory molecules, cell-based therapies such as adoptive transfer of ex-viv

267 l expansion may improve the efficacy of stem cell-based therapies targeting fibrosis.

268 Cs) is crucial for the establishment of stem cell-based therapies targeting the treatment of immunolo

269 vide us with a strong basis for developing T cell-based therapy targeting this shared neoepitope.

270 alian hearts has prompted the need for novel cell-based therapies that can restore contractile functi

271 recent scientific advances in gene-based and cell-based therapies that might translate into novel the

272 atment strategies include the possibility of cell-based therapy that may reduce the severity of lung

273 A prototypic cell-based therapy, the mesenchymal stem cell, has succe

274 In cell-based therapies, therapeutic genes are expressed in

275 00 regenerative medicine products, including cell-based therapies, tissue-engineered biomaterials, sc

276 for the use of Notch-expanded progenitors in cell-based therapies to aid in the recovery of T-cells i

277 s thus provide a rationale for developing NK cell-based therapies to effectively treat MYC-driven lym

278 Cell-based therapies to facilitate chimerism and achieve

279 lls have emerged as potential candidates for cell-based therapies to modulate the immune response in

280 valuate potential strategies for engineering cell-based therapies to overcome tumor associated immune

281 external pallidum could be a new target for cell-based therapies to reduce PD symptoms.

282 e potential provides significant promise for cell-based therapies to restore tissues or organs destro

283 ic stem cells (ESCs) holds great promise for cell-based therapies to treat hematologic diseases.

284 We summarize here the status of cell-based therapies to treat multiple sclerosis and mak

285 establish a strategy for creating autologous cell-based therapies to treat patients with aggressive f

286 Cell-based therapies to treat retinal degeneration are n

287 RPOSE OF REVIEW: This review focuses on stem cell-based therapies to treat skeletal muscle disorders,

288 properties for developing new approaches in cell-based therapy to combat skeletal muscle wasting.

289 T cell adoptive transfer may be useful as a cell-based therapy to improve the efficacy and safety of

290 present the ideal autologous cell source for cell-based therapy to promote remyelination and neuropro

291 em cells (MSCs) are promising candidates for cell-based therapy to treat several diseases and are com

292 stem cell behavior are helping to move stem cell-based therapies toward the clinic.

293 Cell-based therapy using mesenchymal stem cells (MSCs) s

294 Finally, in vivo efficacy of cell-based therapy was assessed in a xenotransplant femo

295 iving or were candidates to receive post-SCT cell-based therapies were not included in this analysis.

296 Moreover, the success of cell-based therapies will depend on a more comprehensive

297 sequent randomized studies to compare T-Rapa cell-based therapy with standard transplantation regimen

298 Cell-based therapies, with or without genetic modificati

299 nt advances in gene, protein replacement, or cell-based therapies, with the purpose of delivering fun

300 romal cells (BMSCs) hold great potential for cell-based therapy, yet the therapeutic efficacy remains